Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug development process for a product with a primary pediatric indication.

Albert J Allen1, David Michelson

  • 1Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. allenaj@lilly.com

The Journal of Clinical Psychiatry
|February 4, 2003
PubMed
Summary

This review covers U.S. drug development for pediatric indications, highlighting FDA regulations and challenges. Atomoxetine for ADHD illustrates modern processes and pediatric drug development complexities.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

International expert consensus on metric-based characterization of robot-assisted total laparoscopic hysterectomy (RATLH).

Surgical endoscopy·2025
Same author

Requirements and special considerations for drug trials with children across six jurisdictions: 1. Clinical trial application review in the regulatory approval process.

Frontiers in medicine·2025
Same author

Requirements and special considerations for drug trials with children across six jurisdictions: 2. Ethics review in the regulatory approval process.

Frontiers in medicine·2025
Same author

A randomized, double-blind, placebo-controlled study of histone deacetylase type 6 inhibition for the treatment of painful diabetic peripheral neuropathy.

Pain reports·2023
Same author

Establishing a global regulatory floor for children's decisions about participation in clinical research.

Pediatric research·2023
Same author

Real-world Adherence to Nusinersen in Adults with Spinal Muscular Atrophy in the US: A Multi-site Chart Review Study.

Journal of neuromuscular diseases·2022

Area of Science:

  • Pharmacology
  • Biomedical Ethics
  • Regulatory Science

Background:

  • The U.S. drug development landscape is evolving, with increased focus on pediatric indications.
  • New U.S. Food and Drug Administration (FDA) regulations and guidance impact pediatric drug development.
  • Historical context of Attention-Deficit/Hyperactivity Disorder (ADHD) treatments shows significant changes over 50 years.

Purpose of the Study:

  • To review the drug development process in the United States for drugs with a primary pediatric indication.
  • To examine practical issues and new FDA regulations pertinent to pediatric drug development.
  • To illustrate modern drug development using Atomoxetine as a case study for ADHD treatment.

Main Methods:

  • Review of current U.S. FDA regulations and guidance for pediatric drug development.

Related Experiment Videos

  • Case study analysis of Atomoxetine, a novel ADHD treatment.
  • Discussion of challenges in pediatric drug development, including ethics, pharmacology, and clinical trials.

    • Main Results:

    • Modern drug development for pediatric indications involves navigating specific regulatory pathways.
    • Atomoxetine's development highlights advancements and challenges compared to older ADHD stimulant treatments.
    • Pediatric drug development presents unique hurdles in biomedical ethics, developmental pharmacology, and trial design.

    Conclusions:

    • Developing drugs for pediatric populations requires addressing specialized regulatory, ethical, and scientific considerations.
    • The FDA's evolving framework aims to improve the development of medications for children.
    • Successful pediatric drug development necessitates a multidisciplinary approach encompassing ethical, pharmacological, and clinical trial expertise.